Cargando…
Maternal–Fetal Drug Development: An Industry Perspective
Medicines and vaccines prescribed to pregnant women often have not had pregnant women or lactating women included in clinical trials and products are often not approved by regulatory agencies for use in pregnant women. As a result, practitioners may need to prescribe medicines and give vaccines to t...
Autores principales: | Burnham, Janelle, Darsey, Edress |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9541578/ https://www.ncbi.nlm.nih.gov/pubmed/36106788 http://dx.doi.org/10.1002/jcph.2124 |
Ejemplares similares
-
Methylphenidate extended-release oral suspension for the treatment of attention-deficit/hyperactivity disorder: a practical guide for pharmacists
por: Caballero, Joshua, et al.
Publicado: (2017) -
The 5((th)) International Conference of Omani Society of Obstetrics and Gynecology (OSOG) in collaboration with the Arab Maternal Fetal Medicine expert group (AMFMEG): Abstracts
Publicado: (2018) -
Chronic maternal inflammation during late gestation impairs subsequent β-cell function but not islet growth in fetal sheep
por: Abebe, M D, et al.
Publicado: (2018) -
Clinical Assessment of Fetal Well‐Being and Fetal Safety Indicators
por: David, Anna L., et al.
Publicado: (2022) -
Sustained maternal inflammation during the early third trimester yields fetal adaptations that impair subsequent skeletal muscle growth and glucose metabolism in sheep
por: Cadaret, Caitlin N, et al.
Publicado: (2018)